Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 3/20 | 0.41 |
| ▸ | RARB | P10826 | 3/20 | 0.41 |
| ▸ | RARG | P13631 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406766 | 0.93 | MAPK1 (0.43) | RARARARBRARGRXRARXRB | |
| SCHEMBL1406614 | 0.82 | RARA (0.41) | RARARARBRARGRXRARXRB | |
| SCHEMBL1406612 | 0.82 | RARA (0.41) | RARARARBRARGRXRARXRB | |
| SCHEMBL1406754 | 0.82 | MAPK1 (0.37) | HSD17B10LMNAHPGDUSP2ALDH1A1 | |
| SCHEMBL2099841 | 0.80 | RARB (0.46) | RARARARBRARGRBP4NR4A1 | |
| SCHEMBL1406320 | 0.80 | RXRA (0.41) | RXRARXRBRXRGNR4A2NR4A1 | |
| SCHEMBL2098805 | 0.79 | RARB (0.46) | RARARARBRARGRBP4NR4A1 | |
| SCHEMBL6424544 | 0.77 | MEN1 (0.33) | RXRARXRBRXRGHSD17B10ALDH1A1 | |
| SCHEMBL1406910 | 0.76 | RBP4 (0.38) | RBP4HSD17B10MEN1MAPK1KMT2A | |
| SCHEMBL1406937 | 0.76 | RBP4 (0.38) | RARBRARGRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513793-B1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2011-03-09 | — | — | EP | claimed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | claimed |
| EP-1513793-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | claimed |
| WO-2003101928-A1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | claimed |
| EP-1513793-B1 | NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2011-03-09 | — | — | EP | disclosed |
| US-7468457-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-23 | — | — | US | disclosed |
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131033-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.